Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A16 Injection in Preterm and Term Infants for RSV LRTI Prevention (Phase Ib/IIa)
CTR20255226Phase 2Active
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SIBP-A16 in respiratory syncytial virus lower respiratory tract infection (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: AE, SAE, AESI, NOCD incidence, RSV neutralizing antibody activity and 1 more. Started Jan 2026; status: active.
02
Drugs
SIBP-A16
03
Conditions
respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on CTR20255226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255226.